[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516732":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":10,"locations":25,"responsibleParty":73,"collaborators":10,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":10,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":10,"overallStatus":91,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adult patients newly diagnosed with ES-SCLC",null,"The study will include consecutive adult patients newly diagnosed with ES-SCLC (patients with the recurrent limited stage disease are also eligible).",[13],"Other: Observational study",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","Observational study","This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.",[9],[21],{"name":22,"affiliation":23,"role":24},"Mauro Zukin","Latin American Cooperative Oncology Group","PRINCIPAL_INVESTIGATOR",[26,39,49,58,67],{"facility":27,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"ÉTICA Clínica AMO - Assistência Multidisciplinar em Oncologia","Salvador","Estado de Bahia","41.950-640","Brazil","BR",{"type":34,"coordinates":35},"Point",[36,37],-38.49096,-12.97563,{"lat":37,"lon":36},{"facility":40,"status":10,"city":41,"state":42,"zip":43,"country":31,"countryCode":32,"cosmosGeoPoint":44,"geoPoint":48,"contacts":10},"Oncologia D'Or Unidade Esperança Pernambuco","Recife","Pernambuco","50.070-480",{"type":34,"coordinates":45},[46,47],-34.88111,-8.05389,{"lat":47,"lon":46},{"facility":50,"status":10,"city":51,"state":10,"zip":52,"country":31,"countryCode":32,"cosmosGeoPoint":53,"geoPoint":57,"contacts":10},"Instituto D'Or de Pesquisa e Ensino RJ","Rio de Janeiro","22.281-100",{"type":34,"coordinates":54},[55,56],-43.18223,-22.90642,{"lat":56,"lon":55},{"facility":59,"status":10,"city":60,"state":10,"zip":61,"country":31,"countryCode":32,"cosmosGeoPoint":62,"geoPoint":66,"contacts":10},"BP - A Beneficência Portuguesa de São Paulo","São Paulo","01.323-030",{"type":34,"coordinates":63},[64,65],-46.63611,-23.5475,{"lat":65,"lon":64},{"facility":68,"status":10,"city":60,"state":10,"zip":69,"country":31,"countryCode":32,"cosmosGeoPoint":70,"geoPoint":72,"contacts":10},"A.C. Camargo Cancer Center","01.509-001",{"type":34,"coordinates":71},[64,65],{"lat":65,"lon":64},{"type":74,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100516732","a-real-world-assessment-of-the-demographic-clinical-characteristics-and-outcomes-of-a-brazilian-cohort-of-previously-untreated-extensive-stage-small-cell-lung-cancer-receiving-durvalumab-combined-with-platinum-etoposide-in-es-sclc-in-brazil-100516732",false,"NCT06008353","A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil","EDUR-BRA","Inclusion Criteria:\n\n* Have a documented diagnosis of ES-SCLC (newly diagnosed patients, as well as limited stage relapsed patients, are eligible);\n* Have been treated with a durvalumab-based regimen for 1L ES-SCLC in the past (retrospective) OR is currently being treated with a durvalumab-based regimen for 1L ES-SCLC (prospective);\n* Male or female adult patients ≥ 18 years of age (as per local Durvalumab approved label);\n* Provision of consent in a signed informed consent form (ICF) (allowing for data to be captured from existing medical records). If the patient´s data is entirely retrospective (i.e., the patient already presented progression, death, or completed 18 months of durvalumab-based treatment), the ICF may be waived, as decided by the local ethics committee.\n\nExclusion Criteria:\n\n* Since the study is observational, there are no Exclusion Criteria. If the patient meets all the Inclusion Criteria, he\u002Fshe will be eligible for the study.","ALL","18 Years",{"count":85,"type":86},60,"ESTIMATED","OBSERVATIONAL","The central objective of this study is to characterize the demographic of an ES-SCLC Brazilian cohort treated with durvalumab. Secondarily, to assess the outcomes of durvalumab-based regimens in 1L treatment of ES-SCLC Brazilian patients from the private health care setting.",[90],"Extensive-stage Small-cell Lung Cancer","ACTIVE_NOT_RECRUITING","2024-12-18",{"date":94,"type":95},"2024-12-19","ACTUAL",{"date":97,"type":95},"2024-01-18",{"date":99,"type":86},"2026-08-31",{"name":5,"class":6},5]